Israel’s “precision medicine” for COVID-19, which tackles the immune overreaction that causes deterioration from the disease, will start a second round of clinical trials in Greece next week.
The inhaled drug EXO-CD24 was given to 30 patients in moderate condition or worse, and all of them recovered, 29 of them within three to five days. In February Tel Aviv’s Ichilov Medical Center revealed that it had invented and started testing the drug, calling it a “huge breakthrough.” It has since been subjected to further testing in vitro and on animals in Israel, and has performed well. Source: Times of Israel
Fair Use Notice:This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.